Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Average Target Price from Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $17.25.

Several equities research analysts recently commented on ENTA shares. HC Wainwright dropped their price objective on shares of Enanta Pharmaceuticals from $27.00 to $18.00 and set a "buy" rating on the stock in a research note on Tuesday, December 24th. JMP Securities reissued a "market outperform" rating and issued a $21.00 price target (down from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. Finally, Robert W. Baird reduced their price objective on Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating for the company in a research report on Tuesday, November 26th.

Enanta Pharmaceuticals Stock Up 8.2 %

Shares of NASDAQ:ENTA traded up $0.40 during trading on Monday, hitting $5.25. The stock had a trading volume of 680,088 shares, compared to its average volume of 610,671. The company has a market capitalization of $111.27 million, a PE ratio of -0.96 and a beta of 0.56. The firm's fifty day moving average is $7.12 and its 200 day moving average is $10.65. Enanta Pharmaceuticals has a 12 month low of $4.71 and a 12 month high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.16) by ($0.20). The firm had revenue of $14.60 million during the quarter, compared to the consensus estimate of $17.99 million. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. Enanta Pharmaceuticals's revenue for the quarter was down 22.8% compared to the same quarter last year. During the same quarter last year, the company posted ($1.33) EPS. Equities research analysts expect that Enanta Pharmaceuticals will post -4.93 EPS for the current fiscal year.

Insider Transactions at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of Enanta Pharmaceuticals stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the sale, the chief executive officer now owns 801,638 shares of the company's stock, valued at approximately $6,461,202.28. This trade represents a 0.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 13.64% of the company's stock.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Rhumbline Advisers raised its position in Enanta Pharmaceuticals by 4.7% in the 2nd quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company's stock worth $448,000 after buying an additional 1,548 shares during the last quarter. US Bancorp DE boosted its holdings in Enanta Pharmaceuticals by 4,933.7% in the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 4,243 shares during the last quarter. American Century Companies Inc. grew its position in Enanta Pharmaceuticals by 35.4% in the 2nd quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company's stock worth $362,000 after purchasing an additional 7,287 shares during the period. Quest Partners LLC raised its stake in Enanta Pharmaceuticals by 65.0% during the 3rd quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company's stock valued at $198,000 after buying an additional 7,535 shares during the last quarter. Finally, FMR LLC lifted its holdings in shares of Enanta Pharmaceuticals by 18.9% during the 3rd quarter. FMR LLC now owns 49,301 shares of the biotechnology company's stock valued at $511,000 after buying an additional 7,839 shares during the period. 94.99% of the stock is owned by hedge funds and other institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.